To hear about similar clinical trials, please enter your email below
Trial Title:
18F-LN1 PET/CT in Urothelial Carcinomas
NCT ID:
NCT06120413
Condition:
Urothelial Carcinoma
Conditions: Official terms:
Carcinoma
Carcinoma, Transitional Cell
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Summary:
The clinical feasibility of 18F-LN1 PET/CT will be evaluated in 30 patients with
urothelial carcinoma, and the results will be compared with those of 18F-FDG.
Detailed description:
This study aims to evaluate the recognition efficiency of 18F-LN1 and 18F-FDG PET imaging
for tumor target Nectin-4 in patients with urothelial carcinoma. The main method is to
compare the results of visually interpreted PET images with histopathological results
(through surgery or biopsy), which are the gold standard for final diagnosis.
Criteria for eligibility:
Study pop:
Patients with clinically suspected or diagnosed urothelial carcinomas
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Age 18 and above
- No gender difference
- Patients who have been diagnosed with, or are clinically highly suspected of,
urothelial carcinomas and have had no other treatment within 3 months
Exclusion Criteria:
- Hypertension that is difficult to control with medication, and systolic blood
pressure exceeding 160mmHg
- Complicated with chronic liver disease, myocardial infarction, stroke
- Female patients who are pregnant (or attempting to become pregnant within six
months), breastfeeding, or unwilling to use contraception
- Abnormal cardiopulmonary function or mental state, unable to tolerate prone lying
for 20 minutes
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Departments of Nuclear Medicine, Sichuan Provincial People's Hospital
Address:
City:
Chengdu
Zip:
610072
Country:
China
Status:
Recruiting
Contact:
Last name:
Hao Wang, Doctor
Phone:
+86-18313820216
Email:
474556259@qq.com
Start date:
November 1, 2023
Completion date:
October 2024
Lead sponsor:
Agency:
Sichuan Provincial People's Hospital
Agency class:
Other
Source:
Sichuan Provincial People's Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06120413
